THERADIAG overview

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, today announced its half-revenue and cash position on June 30, 2023, data that is currently being audited. H1 2023 revenue of €6.7 million In thousands of euros Q2 2022 Q2 2023 Change H1 2022 H1 2023 Change Revenue 3,150 3,383 7.4% 6,264 6,688 6.8% Of which Theranostics revenue 1,578 1,727 9.4% 3,024 3,569 18.0% Of which IVD revenue 1,572 1,656...

Regulatory News: THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in the in vitro diagnosis of autoimmune diseases and theranostics, today announces its annual results for the year ended December 31, 2022, as approved by the Board of Directors on April 11, 2023, and its revenue for the first quarter ended March 31, 2023. The Company's accounts as of December 31, 2022 will be disclosed in the Company's annual financial report, which will be made available to shareholders on...

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, announces today its new financial calendar for 2023, the publication of its annual results for 2022 and its revenue for the first quarter of 2023 is postponed to April 12. Events Dates* 2022 Full-Year Results and 2023 First-Quarter Revenue Wednesday April 12, 2023 Annual General Meeting Wednesday May 24, 2023 2023 First-Half Revenue Monday July...

Regulatory News: The Board of Directors of THERADIAG (ISIN: FR0004197747, Ticker: ALTER), held on March 1 st , 2023, has decided to appoint Mr Christian Policard as Chairman to replace Mr Pierre Morgon, who has resigned, and Mr Simon Davière as Chief Executive Officer to replace Mr Bertrand de Castelnau, who has also resigned, as of March 1 st ,2023. "After more than ten years as an independent director, and then Chairman of the Board, I am closing today a chapter of profound transformation and...

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and Theranostics, today reported its 2022 annual revenue and its cash position at December 31, 2022. 2022 revenue of €12.2 million In thousands of euros FY 2022 FY 2021 % Change Revenue* 12,205 11,125 +9.7% of which: Theranostics 6,357 5,771 +10.1% of which: IVD 5,848 5,354 +9.2% *Figures currently being audited Over the year to December 31, 2022,...

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, today announces its schedule for the publication of financial information for 2023. Events Dates* 2022 Full-Year Annual Revenue Monday January 16, 2023 2022 Full-Year Results Monday April 3, 2023 2023 First-Quarter Revenue Monday 17 April, 2023 Annual General Meeting Tuesday May 16, 2023 2023 First-Half Revenue Monday July 17, 2023 2023...

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, is adjusting its 2026 sales and profitability targets. During the capital increase carried out on 26 November 2021, Theradiag had stated its ambition to reach a revenue of more than €40 million in 5 years while maintaining strict control of its costs. It was expected that the United States would account for approximately half of the sales target, notably through...

Regulatory News: THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and Theranostics, announces the appointment of Crowe HAF by the Company's Board of Directors as independent expert within the framework of the proposed voluntary public tender offer filed by Biosynex. On September 23, 2022, Biosynex filed with the Autorité des marchés financiers (the " AMF ") a proposed voluntary cash tender offer for the shares of the Company that it...